Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 7.45B 6.46B 6.1B 5.54B 10.39B 715B 10.45B 72.86B 28.16B 363B 27.99B 27.37B 1,156B P/E 2026 *
-12.5x
P/E 2027 * -23.5x
Enterprise Value 7.35B 6.37B 6.02B 5.46B 10.24B 705B 10.3B 71.86B 27.77B 358B 27.61B 26.99B 1,140B EV / Sales 2026 *
7.98x
EV / Sales 2027 * 5.46x
Free-Float
99.05%
Yield 2026 *
-
Yield 2027 * -
1 day-5.10%
1 week-19.96%
Current month-25.71%
1 month-21.66%
3 months-38.65%
6 months-38.01%
Current year-43.32%
1 week 44.66
Extreme 44.66
56.16
1 month 44.66
Extreme 44.66
64.19
Current year 44.66
Extreme 44.66
86.74
1 year 44.66
Extreme 44.66
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 01/07/2012
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/05/2000
Director TitleAgeSince
Director/Board Member 64 13/12/2005
Director/Board Member 73 01/05/2002
Director/Board Member 64 25/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 A Others

Chief Technology Officer

110 0.0001%
8/31/26 A Others

Executive/Senior Manager

58 0.0000%
8/31/26 A Others

Founder

98 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-5.10%-19.96%-26.87%+4.50% 7.45B
+0.78%+1.20%-0.81%+27.60% 45.91B
-0.32%+4.61%+43.90%+26.98% 44.25B
-4.36%-5.66%+338.30%+516.88% 41.99B
+0.46%-0.83%+6.38%+73.76% 39.58B
-0.17%-3.22%+10.29%+38.69% 31.08B
-0.65%+5.14%+25.61%+120.17% 17.21B
+3.30%-5.03% - - 16.27B
+2.09%+7.50%+21.44%+38.57% 14.96B
+0.86%+9.05%+0.47%-33.54% 13.42B
Average -0.20%-0.93%+46.52%+90.40% 27.21B
Weighted average by Cap. -0.19%-0.24%+67.43%+119.27%

Financials

2026 *2027 *
Net sales 921M 799M 755M 685M 1.28B 88.39B 1.29B 9.01B 3.48B 44.83B 3.46B 3.38B 143B 1.38B 1.19B 1.13B 1.02B 1.92B 132B 1.93B 13.48B 5.21B 67.05B 5.18B 5.06B 214B
Net income -572M -496M -468M -425M -797M -54.87B -802M -5.59B -2.16B -27.83B -2.15B -2.1B -88.71B -320M -277M -262M -238M -446M -30.68B -448M -3.13B -1.21B -15.56B -1.2B -1.17B -49.61B
Net Debt -103M -89.25M -84.36M -76.58M -144M -9.88B -144M -1.01B -389M -5.01B -387M -378M -15.97B 68.31M 59.2M 55.95M 50.79M 95.2M 6.55B 95.77M 668M 258M 3.32B 257M 251M 10.59B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
16/09/26 $44.84 -5.10% 7,958,214
15/09/26 $47.25 -8.15% 6,812,465
14/09/26 $51.44 -5.11% 5,974,753
11/09/26 $54.21 -2.59% 2,175,778
10/09/26 $55.65 -0.66% 3,057,309
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
44.84USD
Average target price
83.82USD
Spread / Average Target
+86.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!